case_images: PMC11756012_01
case_images: Magnetic resonance imaging of liver metastasis during different anticancer treatment regimens. A: On November 23, 2022, an enhanced abdominal magnetic resonance imaging (MRI) revealed a nodular lesion in the right posterior lobe of the liver, with a maximum cross-section of 2.0 cm x 1.9 cm. The lesion exhibited annular enhancement, indicative of a metastatic lesion; B: On February 21, 2023, follow-up MRI revealed a decrease in the size of the nodular lesion to 1.2 cm x 0.9 cm, with persistent annular enhancement; C: On April 11, 2023, MRI revealed an increase in the size of the lesion to 2.0 cm x 1.9 cm, maintaining annular enhancement; D: On July 5, 2023, the lesion was observed to have decreased in size again, measuring 1.4 cm x 1.0 cm, with annular enhancement still present; E: On October 18, 2023, the MRI showed a further reduction in lesion size to 0.9 cm x 0.6 cm, and no enhancement was noted; F: On January 12, 2024, the final MRI revealed no change in lesion size, remaining at 0.9 cm x 0.6 cm, and no enhancement was observed.
case_images: 100724-g003.jpg
case_images: PMC11756012_01_100724-g003.jpg
case_images: F3
case_images: A follow-up enhanced abdominal MRI revealed a nodular lesion in the right lobe of the liver, showing enhancement and a maximum cross-sectional diameter of approximately 2.0 cm x 1.9 cm (Figure 3A). In February 2023, follow-up enhanced MRI revealed a reduction in the diameter of the liver metastatic lesion to 1.2 cm x 0.9 cm with enhancement (Figure 3B).